The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.75
Bid: 1.60
Ask: 1.90
Change: 0.00 (0.00%)
Spread: 0.30 (18.75%)
Open: 1.75
High: 1.75
Low: 1.75
Prev. Close: 1.75
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Expansion of Treat It to Mental Health Treatments

28 Mar 2024 07:00

RNS Number : 6686I
Kanabo Group PLC
28 March 2024
 

 

28 March 2024

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

 

Expansion of Treat It Clinic to Offer Mental Health Treatments

 

Kanabo Group plc (LSE: KNB) is pleased to announce the expansion of its online clinic, Treat It, to include specialised mental health treatments. This expansion comes at a time when national mental health infrastructure is under extreme pressure, and this service will allow individuals who are suffering from conditions such as anxiety, PTSD or ADHD to securely access to treatments through the Group's digital health platform.

 

As with Treat It's existing pain management offering, the mental health service will focus on secondary care, including prescriptions for alternative medications such as medical cannabis. While studies on the efficacy of medical cannabis in this area remain nascent, some evidence indicates that medicinal cannabis may help alleviate symptoms of conditions such as PTSD.

  

Mental Health in the UK

In 2022, around one in six adults experienced moderate to severe depressive symptoms, an increase from pre-pandemic levels. In the fourth quarter of 2023, around 22% of the adult population experienced a high level of anxiety. The non-profit organisation PTSD Today estimates that around 1 in 10 people in the UK, or around 6.6 million people, might experience PTSD during their lifetime. Meanwhile, mental health services are underserved, with the national situation being described as a crisis or an emergency. This new Clinic offering will provide patients for whom other therapies and medications may not have worked with new opportunities to treat their ailments.

 

Progression in Line with Half-Year Results

This achievement aligns with the Company's current corporate goals, as laid out in its Half-Year Results (published 29 Sept 2023). In 2024, alongside expanding its secondary care offerings to include specialist mental health services, Kanabo has launched two in-pharmacy clinics (as announced on 15 January 2024) to establish a physical presence for its clinics. The Company plans to continue this momentum by expanding its primary care services and extending its footprint into the EU market in the near future.

 

Avihu Tamir, CEO, commented: "Since mental health is the second largest indication for medical cannabis prescriptions in the UK, our expansion into these services is poised to significantly increase our patient intake, revolutionising access and treatment options for those in need."

 

Dr Mehran Afshar, Chief Clinical Director of Treat It, commented: "Mental health is an integral part of overall well-being, yet it often remains overlooked or stigmatised. By expanding our digital health platform to include mental health treatments, we aim to provide patients with access to alternative therapies and raise awareness and destigmatise these conditions. Our multidisciplinary team will work closely with patients to develop personalised treatment plans tailored to their unique needs and circumstances."

 

 

 

 

 

Enquiries:

 

Kanabo Group plc

Avihu Tamir, Chief Executive Officer

Assaf Vardimon, Chief Financial Officer

Ian Mattioli, Non-Executive Chair of the Board

 

via Vigo Consulting

+44 (0)20 7390 0230

Peterhouse Capital Limited (Financial Adviser and Broker)

Eran Zucker / Lucy Williams / Charles Goodfellow

 

+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow

kanabo@vigoconsulting.com

 +44 (0)20 7390 0230

 

About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It - an online clinic an online clinic focused on pain management and mental health treatments.

 

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQVLBLZXLFBBZ
Date   Source Headline
4th Nov 20217:00 amRNSUpdate on Materia Acquisition
29th Oct 20217:00 amRNSTotal Voting Rights
22nd Oct 20217:00 amRNSHalf-year Report
7th Oct 20217:00 amRNSNew Partnership Agreement
30th Sep 20217:00 amRNSTotal Voting Rights
22nd Sep 20217:00 amRNSCBD Line Launched in the UK on HandpickedCBD.com
14th Sep 20217:05 amRNSMateria Receives Licence for Malta Facility
31st Aug 20211:51 pmRNSTotal Voting Rights
17th Aug 202111:05 amRNSSecond Price Monitoring Extn
17th Aug 202111:00 amRNSPrice Monitoring Extension
17th Aug 20217:00 amRNSUpdate: New contract signed by Materia
2nd Aug 20217:01 amRNSUpdate re: Investment & MoU with Hellenic Dynamics
30th Jul 202112:49 pmRNSTotal Voting Rights
26th Jul 202111:05 amRNSSecond Price Monitoring Extn
26th Jul 202111:00 amRNSPrice Monitoring Extension
26th Jul 20217:00 amRNSProposed Acquisition
22nd Jul 20213:32 pmRNSBlock Listing Application
14th Jul 20217:00 amRNSKanabo’s First Medical Cannabis Product in UK
8th Jul 20211:00 pmRNSIssue of Equity
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20217:00 amRNSAppointment of Director & Grant of Options
28th Jun 20213:41 pmRNSResult of AGM
25th Jun 20217:00 amRNSInitial Commercial Scale Production
24th Jun 20213:58 pmRNSIssue of Equity
17th Jun 20212:59 pmRNSIssue of Equity
4th Jun 20217:00 amRNSSupport for New Campaign
3rd Jun 202112:00 pmRNSNotice of AGM
2nd Jun 20219:26 amRNSAnnual Financial Report
26th May 20213:36 pmRNSAdmission of Placing Shares
24th May 20217:00 amRNSPlacing, Investment & MoU with Hellenic Dynamics
20th May 20217:00 amRNSNew EU GMP CBD Manufacturing Agreement
14th May 20212:00 pmRNSIssue of Equity
11th May 20211:09 pmRNSIssue of Equity
6th May 20212:00 pmRNSIssue of Equity
26th Apr 20213:03 pmRNSIssue of Equity
21st Apr 20212:57 pmRNSIssue of Equity
14th Apr 20214:01 pmRNSIssue of Equity
8th Apr 20213:15 pmRNSQ1 Summary
31st Mar 20214:51 pmRNSTotal Voting Rights
30th Mar 20213:26 pmRNSIssue of Equity
26th Mar 20217:00 amRNSPDMR Notification
23rd Mar 20218:47 amRNSPublication of Research Note
16th Mar 20212:42 pmRNSIssue of Equity
9th Mar 202111:06 amRNSSecond Price Monitoring Extn
9th Mar 202111:00 amRNSPrice Monitoring Extension
9th Mar 20217:00 amRNSMedicinal Cannabis Production Agreement
8th Mar 20213:42 pmRNSChange of Registered Address
23rd Feb 20217:00 amRNSUK Medicinal Cannabis Distribution Agreement
22nd Feb 20219:05 amRNSSecond Price Monitoring Extn
22nd Feb 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.